CR11412A - Inhibidores de cinesina como productos terapeuticos para el cancer - Google Patents

Inhibidores de cinesina como productos terapeuticos para el cancer

Info

Publication number
CR11412A
CR11412A CR11412A CR11412A CR11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
cinesine
cancer
therapeutic products
ksp
Prior art date
Application number
CR11412A
Other languages
English (en)
Spanish (es)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11412(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11412A publication Critical patent/CR11412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR11412A 2007-12-14 2010-05-05 Inhibidores de cinesina como productos terapeuticos para el cancer CR11412A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
CR11412A true CR11412A (es) 2010-06-30

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11412A CR11412A (es) 2007-12-14 2010-05-05 Inhibidores de cinesina como productos terapeuticos para el cancer

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CN108025084B (zh) 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
WO2018114578A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
WO2019196111A1 (zh) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2409345T3 (es) * 2004-06-18 2013-06-26 Novartis Ag Derivados y compuestos relacionados de N-(1- (1-bencil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil)benzamida como inhibidores de la proteína quinesina de huso (KSP) para el tratamiento del cáncer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).

Also Published As

Publication number Publication date
EP2229170A1 (en) 2010-09-22
EA201000900A1 (ru) 2011-02-28
MY150214A (en) 2013-12-13
EP2229170B1 (en) 2014-01-22
BRPI0821248A2 (pt) 2015-06-16
US20090239922A1 (en) 2009-09-24
CN101939005B (zh) 2015-12-16
UY31532A1 (es) 2009-08-03
SMP201000095B (it) 2011-09-09
EA018014B1 (ru) 2013-04-30
JP5501976B2 (ja) 2014-05-28
AR069676A1 (es) 2010-02-10
US20130012560A1 (en) 2013-01-10
CA2708822A1 (en) 2009-06-25
AU2008337570A1 (en) 2009-06-25
US8664256B2 (en) 2014-03-04
AU2008337570B2 (en) 2012-04-05
KR20100098394A (ko) 2010-09-06
DOP2010000175A (es) 2010-06-30
ES2459442T3 (es) 2014-05-09
NZ585142A (en) 2012-03-30
CL2008003707A1 (es) 2009-06-05
PA8807801A1 (es) 2009-07-23
ECSP10010248A (es) 2010-07-30
SMAP201000095A (it) 2010-09-10
PE20091451A1 (es) 2009-10-19
IL205831A0 (en) 2010-11-30
JP2011506402A (ja) 2011-03-03
CN101939005A (zh) 2011-01-05
TW200930704A (en) 2009-07-16
US8252832B2 (en) 2012-08-28
TN2010000204A1 (en) 2011-11-11
CO6290651A2 (es) 2011-06-20
WO2009077448A1 (en) 2009-06-25
MA31872B1 (fr) 2010-11-01
GEP20125647B (en) 2012-09-25
GT201000172A (es) 2012-04-30
NI201000091A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
CR11412A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2009000687A1 (es) Compuestos derivados de heterociclos nitrogenados de imidazol, inhibidores de la actividad de cinasa raf; composicion farmaceutica; utiles para el tratamiento del cancer, tal como carcinoma de pulmon, pancreatico, de prostata, tiroides, entre otras.
DOP2010000057A (es) Imidazoles fusionados para el tratamiento del cancer
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CO6761389A2 (es) Inhibidores de nampt y rock
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
ECSP12012140A (es) Compuestos de para la inhibición de inmunoproteasomas
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
GT201400090A (es) 2-tiopirimidinonas
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CO6280510A2 (es) Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa
CO6761294A2 (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)